Table 1.
Clinical characteristics of the patients
| Total, n (%) | BREACH, n (%) | UZ Leuven, n (%) | |
|---|---|---|---|
| Total | 177 (100) | 118 (100) | 59 (100) |
| Male | 79 (45) | 55 (47) | 24 (41) |
| Female | 98 (55) | 63 (53) | 35 (59) |
| Median age (range), y | 29 (3-86) | 28 (18-60) | 31 (3-86) |
| Histology | |||
| NS | 144 (81) | 108 (92) | 36 (61) |
| MC | 16 (9) | 5 (4) | 11 (19) |
| LD | 2 (1) | 1 (1) | 1 (2) |
| LR | 6 (4) | 0 | 6 (10) |
| Unclassifiable | 9 (5) | 4 (3) | 5 (8) |
| Disease stage | |||
| Early stage I to II early favorable | 14 (8) | 1 (1) | 13 (22) |
| Early unfavorable | 135 (76) | 116 (98) | 19 (32) |
| Early NA | 4 (2) | 0 | 4 (7) |
| Advanced stage III to IV | 24 (14) | 1 (1) | 23 (39) |
| EBV status* | |||
| Positive | 19 (11) | 6 (5) | 13 (22) |
| Negative | 113 (64) | 78 (66) | 35 (59) |
| NA | 45 (25) | 34 (29) | 11 (19) |
| Therapy | |||
| ABVD | 87 (49) | 39 (33) | 48 (81) |
| AVD + brentuximab | 79 (45) | 79 (67) | 0 |
| Other† | 11 (7) | 0 | 11 (19) |
| Interim PET‡ | |||
| Positive | 31 (17) | 22 (19) | 9 (15) |
| Negative | 122 (69) | 94 (80) | 28 (48) |
| NA | 24 (14) | 2 (1) | 22 (37) |
| Deceased | 2 (1) | 0 | 2 (3) |
| Relapse | 15 (8) | 6 (5) | 8 (13) |
LD, lymphocyte-depleted; LR, lymphocyte-rich; MC, mixed cellularity; NA, not available; NS, nodular sclerosis.
*
Based on LMP1 immunohistochemistry or EBER in situ hybridization.
†
Other: VEPEMB, OEPA (+COPDAC), DHAP, PLD-COP.
‡
Negative, Deauville 1 to 3; positive, Deauville 4 to 5.